Aurora Cannabis has responded to Curaleaf's attempt to halt its at-the-market (ATM) program, calling Curaleaf's hostile bid undervalued and financially risky due to Curaleaf's heavy debt load. Aurora emphasizes that its ATM program, established before Curaleaf's bid, supports its long-term growth strategy and acquisitions, especially in Canada and the UK. The company's board unanimously recommends shareholders reject Curaleaf's offer by taking no action and not tendering shares, highlighting Aurora's debt-free status and strong cash position as advantages over Curaleaf's indebtedness. Aurora also filed a complaint with the Alberta Securities Commission over regulatory deficiencies in Curaleaf's bid, urging shareholders to consider the risks of accepting the offer.
